TY - JOUR
T1 - “Carcinosarcoma of the ovary, fallopian tube, and peritoneum
T2 - Prognostic factors and treatment modalities”
AU - Rauh-Hain, J. Alejandro
AU - Birrer, Michael
AU - del Carmen, Marcela G.
N1 - Funding Information:
This work was supported by R25CA092203 from the National Cancer Institute at the National Institutes of Health and The Deborah Kelly Center for Outcomes Research, Massachusetts General Hospital .
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Objective Ovarian carcinosarcoma (OCS) is a rare malignancy accounting for only 1–4% of all ovarian cancers. The treatment of OCS is largely based on data from small case series and management of other histologic subtypes of epithelial ovarian cancer. We reviewed the literature pertinent to the pathology, pathogenesis, diagnosis, and management of women with OCS. Methods MEDLINE was searched in English for literature on OCS, focusing on the past 30�years. Given the rarity of this tumor, studies were not limited by design or number of reported patients. Results Molecular, epidemiologic, genetic, and histologic data indicate that most OCS are monoclonal. Patients with OCS generally present with advanced stage disease. Most of the available retrospective studies support the role of cytoreductive surgery in the management of OCS, with optimal debulking associated with improved survival. Platinum-based chemotherapy is the current accepted adjuvant treatment. Given the limited data regarding the management of recurrent OCS, patients are usually treated similarly to women diagnosed with other subtypes of epithelial ovarian cancer. Conclusion OCS represent a rare and aggressive histologic subtype of epithelial ovarian cancer. The goal of surgery is comprehensive staging in patients with early-stage disease and optimal cytoreduction patients with advanced-stage tumors. Platinum-based chemotherapy is the mainstay of adjuvant systemic treatment. Future studies are needed in order to elucidate the molecular basis for OCS and to evaluate the role of targeted therapy in its management.
AB - Objective Ovarian carcinosarcoma (OCS) is a rare malignancy accounting for only 1–4% of all ovarian cancers. The treatment of OCS is largely based on data from small case series and management of other histologic subtypes of epithelial ovarian cancer. We reviewed the literature pertinent to the pathology, pathogenesis, diagnosis, and management of women with OCS. Methods MEDLINE was searched in English for literature on OCS, focusing on the past 30�years. Given the rarity of this tumor, studies were not limited by design or number of reported patients. Results Molecular, epidemiologic, genetic, and histologic data indicate that most OCS are monoclonal. Patients with OCS generally present with advanced stage disease. Most of the available retrospective studies support the role of cytoreductive surgery in the management of OCS, with optimal debulking associated with improved survival. Platinum-based chemotherapy is the current accepted adjuvant treatment. Given the limited data regarding the management of recurrent OCS, patients are usually treated similarly to women diagnosed with other subtypes of epithelial ovarian cancer. Conclusion OCS represent a rare and aggressive histologic subtype of epithelial ovarian cancer. The goal of surgery is comprehensive staging in patients with early-stage disease and optimal cytoreduction patients with advanced-stage tumors. Platinum-based chemotherapy is the mainstay of adjuvant systemic treatment. Future studies are needed in order to elucidate the molecular basis for OCS and to evaluate the role of targeted therapy in its management.
KW - Chemotherapy
KW - Ovarian cancer
KW - Ovarian carcinosarcoma
UR - http://www.scopus.com/inward/record.url?scp=84990246931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84990246931&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2016.06.003
DO - 10.1016/j.ygyno.2016.06.003
M3 - Article
C2 - 27321238
AN - SCOPUS:84990246931
SN - 0090-8258
VL - 142
SP - 248
EP - 254
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -